Conclusions
This is the first study to demonstrate that tofogliflozin is not associated with improved inhibition of carotid wall thickening but exerts long-term positive effects on various cardiovascular risk factors including HbA1c and HDL-C levels, BMI, waist circumference, systolic blood pressure, and baPWV while showing a good safety profile.